Skip Content
Page Banner Image


Sage Therapeutics.

The DIMENSION study offered by Sage Therapeutics, Inc. is investigating SAGE-718 for the treatment of cognitive symptoms associated with Huntington disease (HD) in adults with premanifest or early manifest HD. SAGE-718 has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) in September 2021 as a potential treatment for HD. Fast Track is a process designed to facilitate the development and review of new treatments for serious conditions with unmet medical need, such as HD.

DIMENSION is a Phase 2, randomized, double-blind, placebo-controlled study. The objectives of DIMENSION are to:

  • Evaluate the efficacy of SAGE-718 to reduce cognitive symptoms associated with HD
  • Evaluate the safety and tolerability of SAGE-718 in subjects with HD

The study is registered at

Currently recruiting.

Study Type
Phase II Clinical Trial

Canadian Locations:


Location: Sage Investigational Site
North York, ON  M2K 1E1
Status: Recruiting

Contact: Emily Lefler, PharmD (619) 630-4802

Contact email:


For more detailed information on this study and others and for the most recent updates, please go to is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

We support those facing huntington disease
 Latest Blog


Have questions? Send us an email at:



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up

Copyright © Huntington Society of Canada. All Rights Reserved. Charitable Registration Number 11896 5516 RR0001